Eligibility Module

Eligibility Module

The Eligibility Module contains detailed information about who can participate in the clinical trial. This includes eligibility criteria, age restrictions, gender requirements, healthy volunteer status, and study population descriptions, helping researchers understand who is eligible to participate in the study.

Eligibility Module path is as follows:

Study -> Protocol Section -> Eligibility Module

Eligibility Module


Ignite Creation Date: 2025-12-24 @ 12:51 PM
Ignite Modification Date: 2025-12-24 @ 12:51 PM
NCT ID: NCT00456261
Eligibility Criteria: Inclusion Criteria: * Histologically confirmed non-small cell bronchogenic carcinoma, (adenocarcinoma, or large cell carcinoma) * Patients who have newly diagnosed unresectable stage III or stage IV disease are eligible. * Must be at least 70 years of age * Must have measurable disease by CT scan * Must be able to be up and about and care for themselves * May not have received prior treatment for stage III or IV disease * Must have adequate white and red blood cells and platelets. * Must be able to take Vitamin B12, Folic Acid and dexamethasone as stated in the study * Must be able to understand the nature of this study and give written informed consent * Adequate liver and kidney function Exclusion Criteria: * Past or current history of cancer with the exception of treated non- melanoma skin cancer or carcinoma in-situ of the cervix, or other cancers cured by local therapy alone and have been disease free for five years * Female patients who are pregnant or are lactating are ineligible * History of unstable angina or myocardial infarction within 6 months prior to beginning bevacizumab * Brain metastasis - cancer that has spread to the brain * Major surgical procedure, open biopsy, or significant traumatic injury within 6 weeks of beginning bevacizumab or anticipation of need for major surgical procedure during the course of the study * Full-dose oral or by vein anticoagulation or receiving anti-clotting therapy within 10 days of starting treatment * Serious nonhealing wound, ulcer, or bone fracture * Bleeding or clotting disorders * Uncontrolled high blood pressure or serious heart arrhythmia requiring medication * History of abdominal fistula, gastrointestinal perforation, or intra- abdominal abscess within 6 months prior to beginning bevacizumab * Chronic non-steroidal anti-inflammatory use is not allowed on study * History of stroke or TIAs within the last 6 months Please Note: There are additional inclusion/exclusion criteria. The study center will determine if you meet all of the criteria. If you do not qualify for the trial, study personnel will explain the reasons. If you do qualify, study personnel will explain the trial in detail and answer any questions you may have.
Healthy Volunteers: False
Sex: ALL
Minimum Age: 70 Years
Study: NCT00456261
Study Brief:
Protocol Section: NCT00456261